References

  1. Darnell RB. The importance of defining the paraneoplastic neurologic disorders. N Engl J Med. 1999;340(23):1831-3. PubMed | Google Scholar

  2. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-40. PubMed | Google Scholar

  3. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork data-base: a European study from 20 centers. Arch Neurol. 1998;67(3):330-5. PubMed | Google Scholar

  4. Gatti G, Simsek S, Kurne A, Zurrida S, Naninato P, Veronesi P et al. Paraneoplastic neurological disorders in breast cancer. Breast. 2003;12(3):203-7. PubMed | Google Scholar

  5. Rojas-Marcos I, Rosseau A, Keime-Guibert F, Ramon R, Cartalat-Carel S, Delattre JY et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynaecologic cancer. Medicine. 2003;82(3):216-23. PubMed | Google Scholar

  6. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V et al. Onconeural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 anti-bodies. J Neurol Neurosurg Psychiatry. 1998;80(4):412-6. PubMed | Google Scholar

  7. Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B et al. Paraneoplastic cer-ebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 126(Pt 6):1409-18. PubMed | Google Scholar

  8. Viaccoz A, Honnorat J. Évolutions conceptuelles des syndromes neurologiques paranéoplasiques. Pratique Neurologique-FMC. 2012;3(1):14-25. Google Scholar

  9. Noorani A, Sadiq Z, Minakaran N, Coleman C, Thomas VA, Mokbel K. Paraneoplastic cerebellar degeneration as a presentation of breast cancer-a case report and review of the literature. Int Semin Surg Oncol. 2008;5:8. PubMed | Google Scholar